A comparative study of nivolumab and axitinib in terms of overall survival, treatment continuation, and cost for patients with metastatic renal cell carcinoma

Kimura,Michio; Usami,Eiseki; Teramachi,Hitomi; Yoshimura,Tomoaki

doi:10.3892/mco.2020.1978

A comparative study of nivolumab and axitinib in terms of overall survival, treatment continuation, and cost for patients with metastatic renal cell carcinoma

Authors:
- Michio Kimura
- Eiseki Usami
- Hitomi Teramachi
- Tomoaki Yoshimura
View Affiliations

Affiliations: Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu 503‑8502, Japan, Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu 501‑1196, Japan
Published online on: January 16, 2020 https://doi.org/10.3892/mco.2020.1978
Pages: 284-289

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nivolumab and axitinib has recommended as a second‑line treatment in patients with metastatic renal cell carcinoma (mRCC) after tyrosine kinase inhibitor treatment. In this study, overall survival (OS), treatment continuation, and the cost of nivolumab and axitinib‑the second‑line treatment agents for mRCC‑were compared and examined. Herein, we retrospectively surveyed patients with pathologically confirmed mRCC, treated with nivolumab (n=9) or axitinib (n=16) at Ogaki Municipal Hospital (Ogaki, Japan) between January 2012 and May 2019. The treatment periods for the nivolumab‑ and axitinib‑administered groups were 5.4 (range: 1.4‑21.3) and 3.4 (range: 0.3-28.1) months, respectively (P=0.089). The postponement periods for the nivolumab‑ and axitinib‑administered groups were 7 (range: 0‑186) and 0 (range: 0‑262) days, respectively, and the difference was statistically significant (P=0.008). The median OS for patients treated with nivolumab and axitinib was 12.3 (range: 1.5‑25.5 months) and 9.2 (range: 2.2‑55.0 months) months, respectively (P=0.633). The one‑year cost estimates for axitinib and nivolumab in clinical practice were $60,694.2 and $86,544.4, respectively (P=0.017). We found that despite frequent interruptions in nivolumab administration and a longer postpaonement period for the nivolumab‑administered group than for the axitinib‑administered group, both groups exhibit comparable treatment duration and OS.

View Figures

View References

1	Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al: Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015.PubMed/NCBI View Article : Google Scholar
2	Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, et al: Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 15:804–834. 2017.PubMed/NCBI View Article : Google Scholar
3	Escudier B, Porta C, Schmidinger M, Riou-Leclercq N, Bex A, Khoo V, Gruenvald V and Horwich A: ESMO Guidelines Committee. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 27:v58–v68. 2016.PubMed/NCBI View Article : Google Scholar
4	Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M, et al: In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2:846–856. 2014.PubMed/NCBI View Article : Google Scholar
5	Sonpavde G, Hutson TE and Rini BI: Axitinib for renal cell carcinoma. Expert Opin Investig Drugs. 17:741–748. 2008.PubMed/NCBI View Article : Google Scholar
6	US Department Of Health And Human Services: Common terminology criteria for adverse events (CTCAE) version 4.0. United States, National Cancer Institute, Sept 15, 2009. http://www.acrin.org/Portals/0/Administration/Regulatory/CTCAE_4.02_2009-09-15_QuickReference_5X7.pdf.
7	Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013.PubMed/NCBI View Article : Google Scholar
8	Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, et al: Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial. J Clin Oncol. 33:1430–1407. 2015.PubMed/NCBI View Article : Google Scholar
9	Tomita Y, Fukasawa S, Shinohara N, Kitamura H, Oya M, Eto M, Tanabe K, Kimura G, Yonese J, Yao M, et al: Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the checkmate 025 study. Jpn J Clin Oncol. 47:639–646. 2017.PubMed/NCBI View Article : Google Scholar
10	National Comprehensive Cancer Network: Clinical practice guidelines in oncology: Kidney Cancer. version 2. JNCCN · June 2017.
11	McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD, Smith DC, Brahmer JR, Carvajal RD, Hammers HJ, Puzanov I, et al: Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol. 33:2013–2020. 2015.PubMed/NCBI View Article : Google Scholar
12	De Giorgi U, Cartenì G, Giannarelli D, Basso U, Galli L, Cortesi E, Caserta C, Pignata S, Sabbatini R, Bearz A, et al: Safety and efficacy of nivolumab for metastatic renal cell carcinoma: Real-World results from an expanded access programme. BJU Int. 123:98–105. 2019.PubMed/NCBI View Article : Google Scholar
13	Grimm SE, Armstrong N, Ramaekers BLT, Pouwels X, Lang S, Petersohn S, Riemsma R, Worthy G, Stirk L, Ross J, et al: Nivolumab for treating metastatic or unresectable urothelial cancer: An evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 37:655–667. 2019.PubMed/NCBI View Article : Google Scholar
14	Zargar M, McFarlane T, Chan KKW and Wong WWL: Cost-Effectiveness of nivolumab in recurrent metastatic head and neck squamous cell carcinoma. Oncologist. 23:225–233. 2018.PubMed/NCBI View Article : Google Scholar
15	Matter-Walstra K, Schwenkglenks M, Aebi S, Dedes K, Diebold J, Pietrini M, Klingbiel D, von Moos R and Gautschi O: Swiss Group for Clinical Cancer Research: A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous NSCLC including PD-L1 testing. J Thorac Oncol. 11:1846–1855. 2016.PubMed/NCBI View Article : Google Scholar